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Abstract
Background: Inflammation plays an important role in the pathophysiology of both atherosclerosis and type 2
diabetes and some inflammatory markers may also predict the risk of developing type 2 diabetes. The aims of the
present study were to assess a potential association between circulating levels of inflammatory markers and
hyperglycaemia measured during an acute ST-elevation myocardial infarction (STEMI) in patients without known
diabetes, and to determine whether circulating levels of inflammatory markers measured early after an acute STEMI,
were associated with the presence of abnormal glucose regulation classified by an oral glucose tolerance test
(OGTT) at three-month follow-up in the same cohort.
Methods: Inflammatory markers were measured in fasting blood samples from 201 stable patients at a median time
of 16.5 hours after a primary percutanous coronary intervention (PCI). Three months later the patients performed a
standardised OGTT. The term abnormal glucose regulation was defined as the sum of the three pathological glucose
categories classified according to the WHO criteria (patients with abnormal glucose regulation, n = 50).
Results: No association was found between inflammatory markers and hyperglycaemia measured during the acute
STEMI. However, the levels of C-reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) measured
in-hospital were higher in patients classified three months later as having abnormal compared to normal glucose
regulation (p = 0.031 and p = 0.016, respectively). High levels of CRP (≥ 75 percentiles (33.13 mg/L)) and MCP-1
(≥ 25 percentiles (190 ug/mL)) were associated with abnormal glucose regulation with an adjusted OR of 3.2
(95% CI 1.5, 6.8) and 7.6 (95% CI 1.7, 34.2), respectively.
Conclusion: Elevated levels of CRP and MCP-1 measured in patients early after an acute STEMI were associated
with abnormal glucose regulation classified by an OGTT at three-month follow-up. No significant associations were
observed between inflammatory markers and hyperglycaemia measured during the acute STEMI.
Background
Increased prevalence of unknown impaired glucose tol-
erance and type 2 diabetes has been shown in patients
suffering an acute myocardial infarction (AMI) [1]. Both
the short- and long-term prognoses after an AMI are
worse among individuals with abnormal compared to
individuals with normal glucose regulation [2]. Accord-
ing to guidelines, it is important to diagnose these high-
risk patients with abnormal glucose regulation in order
to initiate lifestyle intervention and optimal medical
treatment [3].
We have recently shown that high levels of HbA1c,
admission glucose, and fasting plasma glucose measured
early in-hospital in patients with an acute ST-elevation
myocardial infarction (STEMI) were predictive to identify
patients with abnormal glucose regulation at three-month
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of an oral glucose tolerance test (OGTT) performed early
after an acute STEMI compared to a new test in a stable
condition three months later [4].
T h e r ei sc o n s i d e r a b l ee v i d e n c et h a ti n f l a m m a t i o n
plays an important role in the pathophysiology of both
atherosclerosis [5] and type 2 diabetes [6] and some
inflammatory markers may also predict the risk of
developing type 2 diabetes [7]. Additionally, inflamma-
tion has been suggested to be the bridging link between
abnormalities in glucose metabolism and atherosclerotic
disorders [8] In order to elucidate a possible association
between hyperglycaemia, abnormal glucose regulation
and inflammation in STEMI patients without known
diabetes we chose to investigate a broad panel of pro-
and anti-inflammatory markers. The acute phase reac-
tant C-reactive protein (CRP), the pro-inflammatory
markers (interleukin 6 (IL-6), interleukin 8 (IL-8),
monocyte chemoattractant protein-1 (MCP-1), tumor
necrosis factor a (TNF-a)), soluble CD40 ligand
(sCD40L), the anti-inflammatory marker adiponectin,
the matrix metalloproteinase-9 (MMP-9) and its inhibi-
tor (tissue inhibitor of metalloproteinase 1 (TIMP-1))
were investigated. We hypothesized that STEMI patients
having abnormal glucose regulation would present with
an increased pro-inflammatory profile.
T h ea i m so ft h es t u d yw e r e1 )t oa s s e s sap o t e n t i a l
association between circulating levels of inflammatory
markers and hyperglycaemia measured during an acute
STEMI in patients without known diabetes and 2) to
identify a possible association between circulating levels
of inflammatory markers measured acutely and abnor-
mal glucose regulation classified by an OGTT at three-
month follow-up in the same cohort.
Methods
Study population
The patient population has been described in detail else-
where [4]. In brief, patients with a primary percutanous
coronary intervention (PCI) treated STEMI were
included if they were stable, without chest pain or nau-
sea, age < 85 years and with serum creatinine < 200
umol/L. Patients with previously known type 2 diabetes
or persistent hyperglycaemia were excluded. Patients
with persistent hyperglycaemia were defined as patients
with both admission plasma glucose > 11 mmol/L and a
fasting capillary glucose level > 8 mmol/L before an
OGTT was performed. STEMI was defined as ST-seg-
ment elevation of ≥ 2m mi nt w oo rm o r ec o n t i g u o u s
chest leads, ≥ 1 mm in two or more limb leads, or new
left bundle-branch block, together with typical symp-
toms (chest pain or discomfort > 20 min duration).
The Regional ethics committee approved the study
and all patients provided written and oral informed
consent.
Laboratory methods
Admission plasma glucose concentration was analysed
from blood samples taken in the catheterisation
laboratory as soon as possible after PCI. Further blood
samples were drawn after an overnight fast for deter-
mination of glucose, HbA1c, for routine analyses by
use of conventional methods and for determination of
CRP, MCP-1, TNF-a, IL-6, sCD40L, IL-8, MMP-9,
TIMP-1, IL-18, and adiponectin. Serum was prepared
by centrifugation within 1 hour at 2500 g for 10 min
and used for all analyses, except MCP-1, which was
determined in citrated plasma (0.129 mmol/L in dilu-
tion 1:10) and sCD40L determined in EDTA plasma,
stored on ice and separated within 30 min by centrifu-
gation at 4°C and 3000 g for 20 min to obtain platelet-
poor plasma. All blood samples were stored at -80°C
until analysis.
CRP and IL-18 were determined by enzyme-linked
immunosorbent assays (DRG Instruments, Marburg/
Lahn, Germany, and Medical Biological Laboratories,
Naku-ku, Nagoya, Japan, respectively). MCP-1, MMP-9,
TIMP-1, IL-6, IL-8, TNF-a, adiponectin and sCD40L
were all measured by enzyme immunoassays from R&D
Systems Europe (Abingdon, Oxon, UK).
In our laboratory, the inter-assay coefficient of varia-
tion were as follows, CRP < 5%, MCP-1 9.0%, IL-6
10.5%, IL-8 10.5%, IL-18 6.5%, TNF-a 8.5%, adiponectin
9.5%, MMP-9 7.4%, TIMP-1 4.4%, and sCD40L 9.5%.
Serum cardiac specific Troponin T (TnT) was mea-
sured by electrochemiluminescence technology for
quantitative measurement (Elecsys 2010, Roche, Man-
nheim, Germany). The inter-assay coefficient of varia-
tion was 7%. TnT maximum was defined as the
maximum value measured in each patient during the
acute STEMI.
Follow- up
Three months after the initial hospitalisation clinical
examination and a standardised oral glucose tolerance
test (OGTT) (75 g glucose in 200 ml water with plasma
glucose measurements at 0 and 120 min) were per-
formed [9]. The classification of glucometabolic state
was based on the result of the OGTT and the patients
were divided into one of the following four categories
defined according to the World Health Organisation cri-
teria [10] (glucose levels given in mmol/L):
Normal Glucose Tolerance (NGT) = OGTT (0 min) <
6.1 and OGTT (2 h) < 7.8
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6.1 < 7.0 and OGTT (2 h) < 7.8
Impaired Glucose Tolerance (IGT) = OGTT (0 min) <
7.0 and OGTT (2 h) ≥ 7.8 < 11.1
Type 2 diabetes (T2DM) = OGTT (0 min) ≥ 7.0 and/
or OGTT (2 h) ≥ 11.1.
The term abnormal glucose regulation was defined as
the sum of IFG, IGT and T2DM.
Left ventricular ejection fraction and infarct size
expressed as percent of left ventricular mass were
assessed at rest at three-month follow-up by Single
Photon Emission Computed Tomography imaging with
technetium 99 m-tetrofosmin [11].
Statistics
The study design was a cohort study and the outcome
was defined as abnormal glucose regulation. We
hypothesised an association between inflammatory vari-
ables and the state of glucose regulation. Continuous
variables were categorised into quartiles. A linear trend
analysis across the quartiles of an inflammatory marker
identified the cut off point used. The Mantel-Haenszel
method was used to highlight potential effect modifica-
tion by the Breslow-Day test of heterogeneity and to
quantify potential confounders [12]. Additional informa-
tion is available online [Additional file 1: Supplemental
Table S1]. The following risk factors were analysed as
potential confounders; gender, age, current smoking,
treated hypertension, TnT maximum, body mass index,
cholesterol, triglycerides, CRP and MCP-1. A logistic
regression model, including a backward elimination pro-
cedure was performed to adjust for the confounders.
Continuous variables are presented as median and 25,
75 percentiles and categorical v a r i a b l e sa sp r o p o r t i o n s .
The correlations between the investigated variables were
assessed by use of Spearman’s rho and adjustments were
performed using a multivariate analysis with logarithmi-
cally transformed data. The STROBE guidelines were
followed [13]. A value of p < 0.05 was considered statis-
tically significant. All analyses were performed using
Epi-info software, 2005, version 3.3.2, except Spearman
correlation coefficient analyses and multiple regressions,
which were made by use of SPSS software, 2006, version
15.0 (SPSS, Chicago, L).
Results
Baseline characteristics
Two hundred and one patients with a primary PCI trea-
ted STEMI were enrolled in the study [4]. Baseline char-
acteristics are shown in Table 1. Notably, BMI was
26 kg/m
2, 82% were men and 61% had single vessel
disease. Fasting blood samples were drawn at a median
time of 20 h and 20 min after the occurrence of symp-
toms and 16 h and 35 min after the primary PCI.
The plasma glucose concentration at admission was
6.9 (6.0, 7.8) mmol/L, the fasting plasma glucose
5.3 mmol/L (4.9, 5.9) and HbA1c 5.5% (5.3, 5.8). As pre-
viously reported, patients defined with abnormal glucose
regulation were older, there were more women, and
they had significantly higher levels of HbA1c, admission
plasma glucose, and fasting plasma glucose measured
in-hospital, compared to patients with normal glucose
regulation [4].
Follow-up characteristics
All patients were reached to follow up. However, one
patient did not perform the OGTT because the level of
fasting glucose measured was above 7 mmol/L. At
three-month follow-up the levels of fasting plasma glu-
cose and HbA1c were 5.2 mmol/L (4.8, 5.6) and 5.6%
(5.4, 5.8), respectively. The prevalence of abnormal glu-
cose regulation based on the OGTT classification was
Table 1 Baseline characteristics of the total population
(n = 201)
Patients
Age (years) 58 (51, 67)
Male 185 (82.6%)
Previous disorder:
Myocardial infarction 16 (7.1%)
Angina pectoris 7 (3.1%)
Hypertension (treated) 58 (25.9%)
Hyperlipidaemia (treated) 20 (8.9%)
Status at baseline
Current smoker 109 (48.7%)
TnT maximum (ug/L) 4.70 (2.45, 8.92)
BMI (kg/m2) 26 (24.4, 28.7)
Waist circumference (cm) 100 (94, 107)
Stent in culprit lesion 215 (96.0%)
Gp IIb/IIIa antagonist treated 79 (35.3%)
Single -coronary vessel disease 139 (62.1%)
Double-coronary vessel disease 64 (28.6%)
Triple-coronary vessel disease 21 (9.4%)
Time from symptoms to balloon (min) 219 (140, 378)
Medication at three months (n = 201)
Aspirin 200 (99.5%)
Clopidogrel 189 (94%)
b-blockers 188 (93.5%)
Lipid lowering agents 194 (96.5%)
Angiotensin converting enzyme-inhibitors 69 (34.3%)
Angiotensin II-receptor blockers 25 (12.4%)
Glucose lowering medication 0
LVEF
a (%) 64 (56, 70)
Infarct size
a, % of left ventricular mass 14.0 (0.0, 29.0)
Data are presented as median (25, 75 percentiles) values or proportions.
BMI: body mass index, LVEF: left ventricular ejection fraction, TnT maximum:
serum cardiac specific Troponin T maximum.
aLVEF and infarct size were
measured at three-month follow-up by SPECT.
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Page 3 of 725% (n = 50). The prevalence of impaired fasting glu-
cose, impaired glucose tolerance, and type 2 diabetes
were 5.5% (n = 11), 14.4% (n = 29) and 5% (n = 10),
respectively. The medications for secondary prevention
recorded were according to current guidelines, i.e. 99.5%
were on aspirin and 96.5% were on lipid lowering agents
(Table 1).
Inflammatory markers and hyperglycaemia
As can be seen from Table 2, there were no associations
between admission glucose and the inflammatory mar-
kers measured whereas significant correlations were
observed between fasting glucose and IL-6 (p = 0.004)
and adiponectin (p = 0.038). However, after adjustment
for age and TnT maximum measured in-hospital, no
significant associations were found (p = 0.14 and
p = 0.095, respectively).
Inflammatory markers and abnormal glucose regulation
Elevated levels of CRP (p = 0.031) and MCP-1 (p =
0.016) measured in-hospital were found in patients clas-
sified with abnormal glucose regulation at three-month
follow-up (Table 3). There was no difference between
the two groups according to the other inflammatory
markers measured (Table 3). Furthermore, only a weak
correlation between MCP-1 and CRP was found (r =
-0.14, p = 0.049).
When dividing the MCP-1 and CRP levels into quar-
tiles, there were significant trends for the presence of
abnormal glucose regulation with increased levels of
both biomarkers (p = 0.005 and p = 0.016, respectively),
identifying a threshold for MCP-1 at the 25 percentile
(190 ug/mL) and for CRP at the 75 percentile (33.13
m g / L )( F i g u r e1 Aa n d1 B ) .I nu n i v a r i a t ea n a l y s e s ,h i g h
levels of CRP (≥ 75 percentile) and MCP-1 (≥ 25
percentile) in-hospital were associated with abnormal
glucose regulation classified at three-month (p = 0.007
and p = 0.004, respectively) (Table 4). CRP remained
associated with abnormal glucose regulation after adjust-
ment for potential confounders with an OR 3.24 (95%
CI 1.54, 6.83) (Table 4). Triglycerides were shown to
modify the association between MCP-1 and abnormal
glucose regulation (Table A online). Consequently, the
patients were divided into two strata with high and low
triglyceride levels. High levels of MCP-1 were indepen-
dently associated with abnormal glucose regulation in
150 patients with triglycerides below the 75th percentile
(1.8 mmol/L) with an OR 7.56 (95% CI 1.67, 34.18).
Discussion
The main results of the present study were that elevated
levels of CRP and MCP-1 measured in patients early
after an acute STEMI were associated with abnormal
glucose regulation defined at three-month follow-up.
Additionally, during the acute STEMI, there were weak,
non-significant associations between fasting glucose and
IL-6 and adiponectin, while there was no association
between admission glucose and the inflammatory mar-
kers measured.
Inflammatory markers and hyperglycaemia
During experimental conditions, induction of hypergly-
caemia in humans has been shown to increase circulat-
ing levels of cytokines and the effect was more
pronounced in subjects with impaired glucose tolerance
suggesting a causal role of hyperglycaemia in the activa-
tion of the inflammation in diabetes [14]. Furthermore,
hyperglycaemia at admission has been reported to be
associated with increased risk of in-hospital mortality
Table 2 Correlations between the inflammatory markers
and admission plasma glucose (APG) and fasting plasma
glucose (FPG), all measured acutely in-hospital
Variables APG FPG
rs pr s p
CRP mg/L 0.04 NS 0.13 NS
MCP-1 pg/mL 0.05 NS -0.11 NS
TNF-a pg/mL 0.06 NS -0.02 NS
IL-6 pg/mL -0.04 NS 0.20 0.004
sCD40L pg/mL -0.06 NS -0.05 NS
IL-8 pg/mL -0.12 NS -0.12 NS
TIMP-1 ng/mL 0.06 NS 0.03 NS
MMP-9 ng/mL 0.13 NS 0.13 NS
IL-18 pg/mL -0.03 NS -0.04 NS
Adiponectin ng/mL -0.03 NS 0.15 0.04
rs indicate Spearman correlation coefficient.
Abbreviations: see main text.
NS: non-significant.
Table 3 Levels of inflammatory markers measured
in-hospital related to normal (NGR) and abnormal
glucose regulation (AGR) categorised by an OGTT after
three months
Variables NGR
(n = 151)
AGR
(n = 50)
P
CRP mg/L 10.99 (5.95, 30.0) 20.91(8.40, 41.98) 0.031
MCP-1 pg/mL 218 (185, 268) 241 (205, 301) 0.016
TNF-a pg/mL 1.51 (1.25, 2.06) 1.58 (1.26, 2.06) 0.996
IL-6 pg/mL 17.16 (11.22, 28.04) 20.88 (13.76, 31.00) 0.131
CD40L pg/mL 63.3 (44.5, 97.4) 64.6 (43.3, 88.8) 0.599
IL-8 pg/mL 15.1 (13.6, 17.8) 15.4 (13.2, 19.4) 0.432
TIMP-1 ng/mL 190 (162, 217) 199 (163, 220) 0.911
MMP-9 ng/mL 502 (341, 664) 539 (414, 748) 0.254
IL-18 pg/mL 269 (203, 333) 288 (239, 359) 0.096
Adiponectin ng/mL 4794 (3006, 7759) 4385 (2806, 7075) 0.474
Median values (25, 75 percentiles) are given.
Abbreviations: see main text.
P-values refer to difference between groups.
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ever, no guidelines defining the level of pathological
hyperglycaemia at admission with an acute myocardial
infarction [17].
It has been shown that patients with a primary PCI
treated STEMI generate a marked, short-term increase
in circulating levels of inflammatory markers [18] and
higher levels of CRP and IL-6 in patients with acute
myocardial infarction and diabetes compared to patients
without diabetes have also been reported [19]. In the
present study we could, however, not reveal any associa-
tion between the acute hyperglycaemia and the inflam-
matory responses. The relatively few patients with
hyperglycaemia at admission may partly explain these
negative results. In addition, we may have missed the
peak levels of the measured inflammatory markers by
the delayed sampling time point. The association found
between fasting glucose and IL-6 and adiponectin prob-
ably reflect a relation to infarct size because it was no
longer significant after adjustment for TnT maximum.
Associations between inflammatory markers and
abnormal glucose regulation
We have recently shown that in patients with a primary
PCI treated STEMI, a very early OGTT should probably
not be recommended because of lack of reproducibility
[4]. However, high levels of admission glucose, fasting
glucose, and HbA1c in these patients were shown to be
associated with abnormal glucose regulation defined at
three-month follow-up [4]. In the present study, search-
ing for novel biomarkers that may associate with abnor-
mal glucose regulation, we found that high levels of CRP
and MCP-1 measured early after an acute STEMI were
associated with abnormal glucose regulation diagnosed in
as t a b l ec i t u a t i o n .T h ea s s o ciations found between high
levels of CRP and MCP-1 measured acutely and abnor-
mal glucose regulation defined three months later might
be influenced by the acute STEMI, which are known to
release several inflammatory mediators from the necrotic
myocardium into the circulation [20].
Our findings may be interpreted along with previous
results showing higher levels of CRP in patients with
abnormal compared to those with normal glucose regu-
lation [21] thus the high levels of CRP measured acutely
may reflect a low-grade systemic inflammation in glu-
cose intolerant patients.
MCP-1 levels have been reported to be elevated in
patients with an acute myocardial infarction [22] and
poor glycemic control has been suggested to induce
high levels of MCP-1 in diabetic patients [23]. Further-
more, increased monocyte recruitment into the suben-
dothelial space has been shown in patients with diabetic
angiopathy and MCP-1 seems to play a key role in this
process [24]. In our study, the association between high
levels of MCP-1 and abnormal glucose regulation may
indicate that patients with an abnormal glucometabolic
status do present with high levels of MCP-1 before the
acute STEMI or it might be suggested that patients with
abnormal glucose regulation respond with higher levels
of MCP-1 in the acute phase, compared to those with
normal glucose regulation.
MCP-1 levels have been shown to correlate with tri-
glyceride levels in post-menopausal women [25] and in
patients with diabetes [23]. In our study the association
between MCP-1 and abnormal glucose regulation was
present in the majority of the patients, but not in
patients with triglycerides above 1.8 mmol/L, suggesting
that in these patients the high levels of triglycerides may
mask the association between MCP-1 and glucose
regulation.
Figure 1 Odds ratios of having abnormal glucose regulation
classified three months after an acute STEMI by quartiles of
MCP-1 (pg/mL, panel A) and CRP (mg/L, panel B) measured in-
hospital. P for trend, (A, p = 0.005) and (B, p = 0.016).
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Page 5 of 7CRP and MCP-1 were associated with abnormal glu-
cose regulation independently of each other, indicating
that these markers probably are involved in different
pathological processes associated with type 2-diabetes.
MCP-1 and IL-8 are functionally related, potent che-
moattractants both being shown to be involved in the
atherosclerotic process [26]. It has previously been
reported that fasting levels of IL-8 correlated with BMI
both in subjects with normal and impaired glucose tol-
erance [27]. In obese subjects without coronary heart
disease, the post-load levels of IL-8 increased after an
OGTT in subjects with impaired glucose tolerance com-
pared to normoglycaemic weight-matched individuals
[27] However, we did not found any association between
IL-8 and abnormal glucose regulation.
Elevated levels of IL-18 have been associated with an
increased risk of developing type 2-diabetes [28]. Also
high levels of MMP-9 and TIMP-2 have been found in
patients with an acute coronary syndrome and type 2
diabetes, probably reflecting an abnormal extracellular
matrix metabolism in these patients [29]. On the con-
trary, circulating levels of adiponectin, which is an anti-
atherogenic, anti-inflammatory and insulin-sensitizing
adipokine, have been shown to be lower in patients with
type 2 diabetes and macro vascular disease than those
without [30]. We found, however, no associations
between abnormal glucose regulation and the levels of
IL-18, MMP-9, TIMP-1, and adiponectin. This may be
explained by the fact that only a small number of our
patients were classified as having type 2-diabetes.
Almost all the patients in the present study were trea-
ted according to guidelines for secondary prevention
with medication, which included lipid lowering agents
and anti-platelet treatment. However, glucose lowering
medication, which could have had a confounding effect
on the glucometabolic classification, was not introduced.
Study limitations
Unstable patients with cardiogenic shock, renal failure,
ongoing chest pain, nausea and persistent hyperglycaemia
were excluded from the study, possibly making a selec-
tion bias towards more glucometabolically normal
patients.
Conclusion
Elevated levels of CRP and MCP-1 measured early after
a primary PCI treated STEMI in patients without pre-
viously known diabetes were associated with abnormal
glucose regulation classified by an OGTT at three-
month follow-up indicating an important role of low
grade inflammation in glucose regulation. There was
however, non-significant association between inflamma-
tory markers and hyperglycaemia during the acute
STEMI in the same cohort
Additional material
Additional file 1: Stratified analysis on major potential confounders
using the Mantel-Haenszel method. Table S1 shows identified effect
modifiers and potential confounders in the associations between CRP
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Abbreviations: see main text.
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